3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
3
Phase EARLY_PHASE1
1
Phase 3
1
Status
Completed
5
Active not recruiting
4
Withdrawn
3
Terminated
2
Recruiting
1
Sponsor Class
INDUSTRY
5
Study Type
Interventional
5
Sponsor
Cancer Type
Lymphoid
5
Other hematologic neoplasm
2
Conditions
Recurrence
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Interventions
Cyclophosphamide
739
Cisplatin
687
Gemcitabine
641
Bevacizumab
615
Carboplatin
604
Paclitaxel
600
Docetaxel
565
Radiotherapy
536
Fluorouracil
405
Oxaliplatin
387
Rituximab
369
Doxorubicin
360
Capecitabine
342
Filgrastim
333
Etoposide
328
Dexamethasone
312
Irinotecan
309
pembrolizumab
279
Leucovorin
274
Cetuximab
267
Cytarabine
242
Erlotinib Hydrochloride
231
Prednisone
227
Nivolumab
227
Trastuzumab
225
Bortezomib
221
Vincristine
220
Methotrexate
207
Pemetrexed
199
fludarabine phosphate
195
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
tisagenlecleucel
×
Clear all
NCT03568461
2025-10-07
ELARA
Novartis
Phase 2
Completed
98 enrolled
9 charts
1 FDA
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts
NCT02445248
2024-04-18
JULIET
Novartis
Phase 2
Completed
115 enrolled
22 charts
1 FDA
NCT02435849
2024-02-13
ELIANA
Novartis
Phase 2
Completed
80 enrolled
39 charts
NCT02228096
2020-11-23
ENSIGN
Novartis
Phase 2
Completed
75 enrolled
41 charts